Pancreatic Cancer Research

ResearcherCincinnati Children's Hospital Medical CenterActive in the last 2 years

Maximilian Reichert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8611-5639; OpenAlex author ID A5073445337. Sources: OpenAlex.

Their work

Papers
58 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
268
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: 4 papers · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 4 papers · 2021: 6 papers · 2022: 9 papers · 2023: 2 papers · 2024: 6 papers · 2025: 10 papers · 2026: 7 papers

Papers 50 of 58

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. Co-author DOI 10.1007/s11523-026-01236-x↗
  3. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Co-author DOI 10.1038/s41419-026-09075-4↗
  4. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Co-author DOI 10.1038/s41467-026-73189-8↗
  5. Multicellular rosette formation guides epithelial tissue assembly in pancreatic ductal adenocarcinoma cell organoids. Co-author DOI 10.1073/pnas.2512284123↗
  6. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  7. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Last author DOI 10.64898/2026.06.26.734719↗
  8. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  9. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  10. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  11. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  12. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41551-024-01273-9↗
  13. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Co-author DOI 10.1038/s44320-025-00085-6↗
  14. A 3D patternoid model for the reproducible characterization of invasive phenotypes and drug sensitivity in PDAC. Co-author DOI 10.1039/d5lc00203f↗
  15. The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Interactions in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-25-1085↗
  16. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Last author DOI 10.1172/jci.insight.169105↗
  17. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  18. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  19. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  20. Coexisting mechanisms of luminogenesis in pancreatic cancer-derived organoids. Co-author DOI 10.1016/j.isci.2024.110299↗
  21. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  22. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  23. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. Co-author DOI 10.1055/a-2257-3171↗
  24. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  25. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  26. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  27. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Co-author DOI 10.1002/path.5906↗
  28. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  29. A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes. Last author DOI 10.1016/j.gastha.2022.08.008↗
  30. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  31. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2105691119↗
  32. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  33. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  34. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Last author DOI 10.15252/emmm.202114876↗
  35. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Last author DOI 10.1053/j.gastro.2020.09.010↗
  36. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  37. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  38. Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance. Co-author DOI 10.1158/1535-7163.mct-20-0981↗
  39. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  40. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  41. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  42. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  43. Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275↗
  44. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Last author DOI 10.1172/jci.insight.137809↗
  45. PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells. Co-author DOI 10.1038/s41388-019-0725-6↗
  46. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  47. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  48. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2017.12.004↗
  49. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  50. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗

Closest collaborators

The 25 strongest of 268 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 27 shared papers, 2013–2026 · strength 3.10
  2. Dieter Saur · 25 shared papers, 2013–2026 · strength 3.01
  3. Roland Michael Schmid · 23 shared papers, 2013–2026 · strength 2.68
  4. Roland Rad · 21 shared papers, 2017–2026 · strength 2.48
  5. Matthias Wirth · 17 shared papers, 2013–2026 · strength 1.82
  6. Felix Orben · 11 shared papers, 2020–2026 · strength 1.51
  7. Christian Schneeweis · 11 shared papers, 2018–2026 · strength 1.36
  8. Aristeidis Papargyriou · 7 shared papers, 2020–2025 · strength 1.33
  9. Carolin Schneider · 9 shared papers, 2022–2026 · strength 1.32
  10. Lukas Krauß · 8 shared papers, 2022–2026 · strength 1.19
  11. Andreas R. Bausch · 4 shared papers, 2024–2026 · strength 1.15
  12. Elisabeth Heßmann · 7 shared papers, 2021–2026 · strength 1.05
  13. Hana Algül · 8 shared papers, 2013–2026 · strength 0.99
  14. H. Carlo Maurer · 7 shared papers, 2018–2026 · strength 0.96
  15. Volker Ellenrieder · 6 shared papers, 2021–2026 · strength 0.93
  16. Oliver Holger Krämer · 9 shared papers, 2013–2026 · strength 0.93
  17. Wilko Weichert · 9 shared papers, 2018–2025 · strength 0.89
  18. İhsan Ekin Demir · 6 shared papers, 2021–2025 · strength 0.87
  19. Katja Peschke · 6 shared papers, 2020–2025 · strength 0.86
  20. Marian Grade · 5 shared papers, 2022–2026 · strength 0.83
  21. Zahra Dantes · 9 shared papers, 2018–2025 · strength 0.83
  22. Zonera Hassan · 8 shared papers, 2017–2022 · strength 0.77
  23. Stefanie Bärthel · 5 shared papers, 2022–2026 · strength 0.76
  24. Bernhard Küster · 5 shared papers, 2022–2025 · strength 0.73
  25. Michael B. Ghadimi · 4 shared papers, 2024–2026 · strength 0.71

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.